Gene delivery nanoparticles to modulate angiogenesis

Jayoung Kim, Adam C. Mirando, Aleksander S. Popel, Jordan J. Green

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Angiogenesis is naturally balanced by many pro- and anti-angiogenic factors while an imbalance of these factors leads to aberrant angiogenesis, which is closely associated with many diseases. Gene therapy has become a promising strategy for the treatment of such a disordered state through the introduction of exogenous nucleic acids that express or silence the target agents, thereby engineering neovascularization in both directions. Numerous non-viral gene delivery nanoparticles have been investigated towards this goal, but their clinical translation has been hampered by issues associated with safety, delivery efficiency, and therapeutic effect. This review summarizes key factors targeted for therapeutic angiogenesis and anti-angiogenesis gene therapy, non-viral nanoparticle-mediated approaches to gene delivery, and recent gene therapy applications in pre-clinical and clinical trials for ischemia, tissue regeneration, cancer, and wet age-related macular degeneration. Enhanced nanoparticle design strategies are also proposed to further improve the efficacy of gene delivery nanoparticles to modulate angiogenesis.

Original languageEnglish (US)
Pages (from-to)20-43
Number of pages24
JournalAdvanced Drug Delivery Reviews
StatePublished - Sep 15 2017


  • Age-related macular degeneration
  • Gene therapy
  • Ischemia
  • Non-viral
  • Polymeric nanoparticles
  • Tissue engineering
  • Tumor
  • Wound healing

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Gene delivery nanoparticles to modulate angiogenesis'. Together they form a unique fingerprint.

Cite this